Literature DB >> 28770417

Fungal Pathogens in CF Airways: Leave or Treat?

A Singh1, A Ralhan1, C Schwarz2, D Hartl1, A Hector3.   

Abstract

Chronic airway infection plays an essential role in the progress of cystic fibrosis (CF) lung disease. In the past decades, mainly bacterial pathogens, such as Pseudomonas aeruginosa, have been the focus of researchers and clinicians. However, fungi are frequently detected in CF airways and there is an increasing body of evidence that fungal pathogens might play a role in CF lung disease. Several studies have shown an association of fungi, particularly Aspergillus fumigatus and Candida albicans, with the course of lung disease in CF patients. Mechanistically, in vitro and in vivo studies suggest that an impaired immune response to fungal pathogens in CF airways renders them more susceptible to fungi. However, it remains elusive whether fungi are actively involved in CF lung disease pathologies or whether they rather reflect a dysregulated airway colonization and act as microbial bystanders. A key issue for dissecting the role of fungi in CF lung disease is the distinction of dynamic fungal-host interaction entities, namely colonization, sensitization or infection. This review summarizes key findings on pathophysiological mechanisms and the clinical impact of fungi in CF lung disease.

Entities:  

Keywords:  Aspergillus fumigatus; Candida albicans; Cystic fibrosis; Exophiala dermatitidis; Fungal colonization; Pneumocystis jirovecii

Mesh:

Substances:

Year:  2017        PMID: 28770417     DOI: 10.1007/s11046-017-0184-y

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  222 in total

1.  Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility.

Authors:  M A Jabra-Rizk; T F Meiller; C E James; M E Shirtliff
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

Authors:  Patrick A Flume; Donald R VanDevanter; Elizabeth E Morgan; Michael N Dudley; Jeffery S Loutit; Scott C Bell; Eitan Kerem; Rainald Fischer; Alan R Smyth; Shawn D Aaron; Douglas Conrad; David E Geller; J Stuart Elborn
Journal:  J Cyst Fibros       Date:  2016-02-04       Impact factor: 5.482

3.  Prospective multicenter study of Pneumocystis jirovecii colonization among cystic fibrosis patients in France.

Authors:  Francisca Hernández-Hernández; Emilie Fréalle; Patrick Caneiro; Julia Salleron; Isabelle Durand-Joly; Isabelle Accoceberry; Jean-Philippe Bouchara; Benoit Wallaert; Eduardo Dei-Cas; Laurence Delhaes
Journal:  J Clin Microbiol       Date:  2012-09-26       Impact factor: 5.948

4.  Pneumocystis carinii carriage among cystic fibrosis patients, as detected by nested PCR.

Authors:  A Sing; A M Geiger; M Hogardt; J Heesemann
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

5.  Pseudomonas-Candida interactions: an ecological role for virulence factors.

Authors:  Deborah A Hogan; Roberto Kolter
Journal:  Science       Date:  2002-06-21       Impact factor: 47.728

6.  The macrophage-inducible C-type lectin, mincle, is an essential component of the innate immune response to Candida albicans.

Authors:  Christine A Wells; Judith A Salvage-Jones; Xin Li; Kelly Hitchens; Suzanne Butcher; Rachael Z Murray; Anthony G Beckhouse; Yu-Lan-Sandra Lo; Silvia Manzanero; Christian Cobbold; Kate Schroder; Bo Ma; Sally Orr; Lauren Stewart; Daniel Lebus; Peter Sobieszczuk; David A Hume; Jennifer Stow; Helen Blanchard; Robert B Ashman
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

7.  TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells.

Authors:  Gerrit John; Ali O Yildirim; Bruce K Rubin; Dieter C Gruenert; Markus O Henke
Journal:  Am J Respir Cell Mol Biol       Date:  2009-06-05       Impact factor: 6.914

Review 8.  Immunological mechanisms behind the cystic fibrosis-ABPA link.

Authors:  Dominik Hartl
Journal:  Med Mycol       Date:  2008-06-10       Impact factor: 4.076

9.  Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab).

Authors:  Adaobi Kanu; Kalpana Patel
Journal:  Pediatr Pulmonol       Date:  2008-12

10.  The beta-glucan receptor dectin-1 recognizes specific morphologies of Aspergillus fumigatus.

Authors:  Chad Steele; Rekha R Rapaka; Allison Metz; Shannon M Pop; David L Williams; Siamon Gordon; Jay K Kolls; Gordon D Brown
Journal:  PLoS Pathog       Date:  2005-12-09       Impact factor: 6.823

View more
  9 in total

1.  Fungal Respiratory Infections in Cystic Fibrosis (CF): Recent Progress and Future Research Agenda.

Authors:  Jean-Philippe Bouchara; Françoise Symoens; Carsten Schwarz; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2018-02       Impact factor: 2.574

2.  Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis.

Authors:  Gina Hong; Kevin J Psoter; Mark T Jennings; Christian A Merlo; Michael P Boyle; Denis Hadjiliadis; Steven M Kawut; Noah Lechtzin
Journal:  J Cyst Fibros       Date:  2018-02-12       Impact factor: 5.482

3.  Effect of Candida albicans bronchial colonization on hospital-acquired bacterial pneumonia in patients with systemic lupus erythematosus.

Authors:  Yuetian Yu; Jia Li; Suli Wang; Yuan Gao; Hui Shen; Liangjing Lu
Journal:  Ann Transl Med       Date:  2019-11

4.  Fungal Diseases in the 21st Century: The Near and Far Horizons.

Authors:  Arturo Casadevall
Journal:  Pathog Immun       Date:  2018-09-25

5.  Coexistence of Candida species and bacteria in patients with cystic fibrosis.

Authors:  Johanna Haiko; Baharak Saeedi; Gabriella Bagger; Ferenc Karpati; Volkan Özenci
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-09       Impact factor: 3.267

6.  Urban Life as Risk Factor for Aspergillosis.

Authors:  Claudia Grehn; Patience Eschenhagen; Svenja Temming; Uta Düesberg; Konrad Neumann; Carsten Schwarz
Journal:  Front Cell Infect Microbiol       Date:  2020-11-02       Impact factor: 5.293

7.  Small Molecule CCR4 Antagonists Protect Mice from Aspergillus Infection and Allergy.

Authors:  Silvia Bozza; Rossana Giulietta Iannitti; Marilena Pariano; Giorgia Renga; Claudio Costantini; Luigina Romani; Jagadeesh Bayry
Journal:  Biomolecules       Date:  2021-02-25

Review 8.  The Human Mycobiome in Chronic Respiratory Diseases: Current Situation and Future Perspectives.

Authors:  Juan de Dios Caballero; Rafael Cantón; Manuel Ponce-Alonso; Marta María García-Clemente; Elia Gómez G de la Pedrosa; José Luis López-Campos; Luis Máiz; Rosa Del Campo; Miguel Ángel Martínez-García
Journal:  Microorganisms       Date:  2022-04-13

9.  Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function.

Authors:  Uta Düesberg; Julia Wosniok; Lutz Naehrlich; Patience Eschenhagen; Carsten Schwarz
Journal:  Sci Rep       Date:  2020-11-04       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.